LID.L Regulatory News (LID)

15 Mar 2005 07:02

LiDCO Group Plc15 March 2005 For immediate release 15 March 2005 LiDCO GROUP PLC ("LiDCO") Lithium Chloride Mutual Recognition Approvals in Four Further European Territories LiDCO Group plc, (AIM: LID) the UK-based cardiovascular monitoring company, ispleased to announce today that four further European country approvals ofLithium Chloride for use with the LiDCOplus System have been granted in theterritories of Ireland, Norway, Sweden and Bulgaria. Lithium Chloride is usedin conjunction with the LiDCOplus System to provide an absolute measure of apatients' cardiac output. These latest registrations now provide LiDCO with full marketing approval intwelve European countries including UK, Spain, Germany, Austria, Italy, CzechRepublic, Belgium and Holland. Commenting on the four European approvals, Dr Terry O'Brien, LiDCO's CEO, said:"We have now successfully registered the lithium chloride injection as apharmaceutical (in-vivo diagnostic) in the majority of the major Europeanmarkets. Europe is the most developed territory for the adoption of advancedminimally invasive cardiovascular monitoring. Following on from our recentproduct launches in Germany, Austria and Italy, we expect the growth in Europeansales to be further accelerated by these additional territories in 2005." For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) terry@lidco.com 020 7749 1500 Buchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Notes for Editors LiDCO is a leading developer of minimally invasive, computer-based hemodynamicmonitoring equipment and disposables used primarily for the management ofcritical care and cardiovascular risk hospital patients. The Company's currentproducts are: • the LiDCOplus and PulseCO monitors, computer-based platforms for displaying a range of real-time continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; and • the LiDCO disposable for accurately determining cardiac output in a minimally-invasive manner. Lithium dilution calibrated waveform analysis The LiDCOplus monitor uses arterial pressure waveform analysis, in conjunctionwith Lithium dilution cardiac output calibration. Lithium does not occurnaturally in the body. Making this a patentable reference indicator. Theinjected lithium is used in trace amounts as an in vivo diagnostic, not atherapeutic drug, to calibrate the PulseCO continuous beat to beat software.The measurement of the marker lithium ion concentration in blood is made througha proprietary lithium selected ion sensor attached to existing radial or otherperipheral arterial lines. The lithium is injected into the venous circulationvia a central venous or peripheral venous line. The lithium cardiac outputdetermination is then used to calibrate cardiac output continuously from thearterial pulse power profile of the pressure waveform. This information is provided by RNS The company news service from the London Stock Exchange